Ziconotide is an analgesic agent and has been used to treat neuropathic and non-neuropathic pain. Ziconotide acts by binding to N-type calcium channels situated on the terminal part of primary afferent neurons of the nociceptive pathway therefore reducing synaptic transmission with potent antinociceptive effects.
CAT No: 10-101-62
CAS No: 107452-89-1
Synonyms/Alias: Ziconotide;Prialt;omega-conotoxin MVIIA;SNX-111;107452-89-1;omega-Conotoxin M VIIA;Ziconotida;omega-Conopeptide MVIIA (Conus);DRG-0250;UNII-7I64C51O16;HSDB 7609;MFCD00145036;150770-63-1;DTXSID60883174;omega-Conotoxin M VIIA (reduced), cyclic (1-16),(8-20),(15-25)-tris(disulfide);7I64C51O16;H-Cys-Lys-Gly-Lys-Gly-Ala-Lys-Cys-Ser-Arg-Leu-Met-Tyr-Asp-Cys-Cys-Thr-Gly-Ser-Cys-Arg-Ser-Gly-Lys-Cy;omega-Conotoxin mviia, conus magus;Ziconotide [USAN:INN];ziconotidum;o-Conotoxin MVIIA;.omega.-conotoxin m viia;ZICONOTIDE (MART.);GTPL2536;CHEMBL4594214;N02BG08;CHEBI:135912;CHEBI:142406;DTXCID901323852;HY-P0062;AKOS015994641;AC-8938;AT42420;HS-2032;FC110295;omega-Conotoxin MVIIA, >=95% (HPLC);CS-0015087;NS00068028;?-Conotoxin M VIIA Acetate; ?-Conopeptide MVIIA Acetate; Prialt Acetate; SNX 111;;L-Cysteinyl-L-lysylglycyl-L-lysylglycyl-L-alanyl-L-lysyl-L-cysteinyl-L-seryl-L-arginyl-L-leucyl-L-methionyl-L-tyrosyl-L-alpha-aspartyl-L-cysteinyl-L-cysteinyl-L-threonylglycyl-L-seryl-L-cysteinyl-L-arginyl-L-serylglycyl-L-lysyl-L-cysteinamide cyclic (1-16),(8-20),(15-25)-tris(disulfide);
Quick InquiryCustom Peptide SynthesisPeptide Library Construction and Screening
Powerful screening tools in biological and chemical research
M.F/Formula | C102H172N36O32S7 |
M.W/Mr. | 2639.2 |
Sequence | One Letter Code:CKGKGAKCSRLMYDCCTGSCRSGKC Three Letter Code:H-Cys(1)-Lys-Gly-Lys-Gly-Ala-Lys-Cys(2)-Ser-Arg-Leu-Met-Tyr-Asp-Cys(3)-Cys(1)-Thr-Gly-Ser-Cys(2)-Arg-Ser-Gly-Lys-Cys(3)-NH2 |
Appearance | Ziconotide (SNX-111), a peptide, is a potent and selective block of N-type calcium channels antagonist. Ziconotide reduces synaptic transmission, and can be used for chronic pain research. |
Activity | Antagonist |
Target | Calcium Channel |
Shipping Condition | Room temperature in continental US; may vary elsewhere. |
InChI | InChI=1S/C102H172N36O32S7/c1-50(2)34-63-91(161)127-62(26-33-171-5)90(160)129-64(35-53-22-24-54(143)25-23-53)92(162)130-65(36-78(148)149)93(163)135-72-48-175-173-45-69(80(108)150)133-86(156)58(18-8-12-29-105)121-76(146)39-117-85(155)66(41-139)131-88(158)61(21-15-32-114-102(111)112)126-96(166)70-46-176-177-47-71(97(167)132-68(43-141)95(165)125-60(87(157)128-63)20-14-31-113-101(109)110)134-89(159)59(19-9-13-30-106)123-81(151)51(3)119-74(144)37-115-83(153)56(16-6-10-27-103)120-75(145)38-116-84(154)57(17-7-11-28-104)124-82(152)55(107)44-172-174-49-73(137-98(72)168)99(169)138-79(52(4)142)100(170)118-40-77(147)122-67(42-140)94(164)136-70/h22-25,50-52,55-73,79,139-143H,6-21,26-49,103-107H2,1-5H3,(H2,108,150)(H,115,153)(H,116,154)(H,117,155)(H,118,170)(H,119,144)(H,120,145)(H,121,146)(H,122,147)(H,123,151)(H,124,152)(H,125,165)(H,126,166)(H,127,161)(H,128,157)(H,129,160)(H,130,162)(H,131,158)(H,132,167)(H,133,156)(H,134,159)(H,135,163)(H,136,164)(H,137,168)(H,138,169)(H,148,149)(H4,109,110,113)(H4,111,112,114)/t51-,52+,55-,56-,57-,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,68-,69-,70-,71-,72-,73-,79-/m0/s1 |
InChI Key | BPKIMPVREBSLAJ-QTBYCLKRSA-N |
2. Emerging applications of nanotechnology for diagnosis and therapy of disease: a review
4. Peptides as Active Ingredients: A Challenge for Cosmeceutical Industry
5. Autoinhibition and phosphorylation-induced activation of phospholipase C-γ isozymes
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at info@creative-peptides.com. We will endeavor to provide highly satisfying products and services.